Novel emerging biomarkers to immunotherapy in kidney cancer
The treatment of metastatic renal cell carcinoma has significantly evolved in recent years, particularly with the advent of novel immune checkpoint inhibitors (ICI). Despite the striking benefits observed on a population level, outcomes vary and some patients do not respond to ICI-based regimens, ul...
Saved in:
Main Authors: | Yasser Ged, Martin H. Voss |
---|---|
Format: | article |
Language: | EN |
Published: |
SAGE Publishing
2021
|
Subjects: | |
Online Access: | https://doaj.org/article/85f04da038e547b387181e4738d986d2 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Indication-specific tumor evolution and its impact on neoantigen targeting and biomarkers for individualized cancer immunotherapies
by: Andrew Wallace, et al.
Published: (2021) -
Cancer immunology and immunotherapy
by: Xiubao Ren
Published: (2021) -
Novel potent anti-STEAP1 bispecific antibody to redirect T cells for cancer immunotherapy
by: Hong-fen Guo, et al.
Published: (2021) -
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma
by: Amaia Lujambio, et al.
Published: (2021) -
Advances in Biomarkers for Immunotherapy of Non-small Cell Lung Cancer
by: Chuan HUANG, et al.
Published: (2021)